Literature DB >> 16283153

[Neoadjuvant chemotherapy of breast carcinomas: what post-therapeutic (preoperative) information is provided by quantitative dynamic MRI?].

K Wasser1, S K Klein, H Junkermann, H P Sinn, S Darai, W Neff, H U Kauczor, S Delorme.   

Abstract

PURPOSE: The aim of this study was to evaluate whether quantitative changes in contrast enhancement (CE) after neoadjuvant chemotherapy (NC) are associated with histological signs of tumor regression and whether quantitative dynamic MRI (dMRI) is capable of accurately assessing preoperative tumor size compared to mammography (MG) and ultrasound (US).
METHODS: Thirty-one patients with breast cancer underwent MRI before and after NC. Dynamic CE was measured using a turbo-FLASH sequence and quantified by a two-compartment model, where two parameters, k(ep) (distribution constant rate) and A (amplitude), were calculated and color mapped.
RESULTS: When tumors had signs of histological regression in the operative specimen (n=17) decrease of the parameters A and k(ep) was significantly more marked compared to tumors without regression (n=12). The correlation between tumor size measured by dMRI and histopathology was 0.81 when areas of unspecific CE were included; when they were not included the correlation was 0.66 and tumor size was systematically underestimated. In 26 patients dMRI was retrospectively compared with MG (r=0.51; dMRI, r=0.80) and in 22 patients with US (r=0.60; dMRI, r=0.75).
CONCLUSION: Changes in dynamic CE are associated with histological tumor regression. Quantitative dMRI enables a valid assessment of tumor residue and is superior to MG and US. Remaining unspecific CE within the original tumor site should be considered as potentially malignant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16283153     DOI: 10.1007/s00117-005-1303-1

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  25 in total

1.  MRI of breast cancer: influence of chemotherapy on sensitivity.

Authors:  A Rieber; H Zeitler; H Rosenthal; J Görich; R Kreienberg; H J Brambs; R Tomczak
Journal:  Br J Radiol       Date:  1997-05       Impact factor: 3.039

Review 2.  The role of neoadjuvant chemotherapy for breast cancer treatment.

Authors:  Tadashi Ikeda; Hiromitsu Jinno; Akira Matsu; Shigeru Masamura; Masaki Kitajima
Journal:  Breast Cancer       Date:  2002       Impact factor: 4.239

3.  Pathophysiologic basis of contrast enhancement in breast tumors.

Authors:  M V Knopp; E Weiss; H P Sinn; J Mattern; H Junkermann; J Radeleff; A Magener; G Brix; S Delorme; I Zuna; G van Kaick
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

Review 4.  MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy.

Authors:  M V Knopp; G Brix; H J Junkermann; H P Sinn
Journal:  Magn Reson Imaging Clin N Am       Date:  1994-11       Impact factor: 2.266

5.  [A pharmacokinetic analysis of Gd-DTPA enhancement in MRT in breast carcinoma].

Authors:  T Hess; M V Knopp; U Hoffmann; G Brix; H Junkermann; I Zuna; D von Fournier; G van Kaick
Journal:  Rofo       Date:  1994-06

6.  Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.

Authors:  Savannah C Partridge; Jessica E Gibbs; Ying Lu; Laura J Esserman; Dan Sudilovsky; Nola M Hylton
Journal:  AJR Am J Roentgenol       Date:  2002-11       Impact factor: 3.959

7.  MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation.

Authors:  P T Weatherall; G F Evans; G J Metzger; M H Saborrian; A M Leitch
Journal:  J Magn Reson Imaging       Date:  2001-06       Impact factor: 4.813

8.  [Imaging methods for evaluating the response of breast carcinoma to preoperative chemotherapy].

Authors:  H Junkermann; D von Fournier
Journal:  Radiologe       Date:  1997-09       Impact factor: 0.635

Review 9.  [Echomorphology of breast cancer].

Authors:  J Teubner; M Bohrer; G van Kaick; M Georgi
Journal:  Radiologe       Date:  1993-05       Impact factor: 0.635

10.  Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Laura Martincich; Filippo Montemurro; Giovanni De Rosa; Vincenzo Marra; Riccardo Ponzone; Stefano Cirillo; Marco Gatti; Nicoletta Biglia; Ivana Sarotto; Piero Sismondi; Daniele Regge; Massimo Aglietta
Journal:  Breast Cancer Res Treat       Date:  2004-01       Impact factor: 4.872

View more
  4 in total

1.  Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.

Authors:  Aida Kuzucan; Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Peter T Fwu; Hon J Yu; David J B Hsiang; Karen T Lane; John A Butler; Stephen A Feig; Min-Ying Su
Journal:  Clin Breast Cancer       Date:  2012-04       Impact factor: 3.225

2.  Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.

Authors:  Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Aida Kuzucan; Hon J Yu; Philip M Carpenter; Stephen A Feig; Muqing Lin; David J B Hsiang; Karen T Lane; John A Butler; Orhan Nalcioglu; Min-Ying Su
Journal:  Radiology       Date:  2011-08-30       Impact factor: 11.105

3.  [Therapy monitoring of neoadjuvant therapy with MRI. RECIST and functional imaging].

Authors:  S Grandl; M Ingrisch; K Hellerhoff
Journal:  Radiologe       Date:  2014-03       Impact factor: 0.635

4.  Detection of Post-Therapeutic Effects in Breast Carcinoma Using Hard X-Ray Index of Refraction Computed Tomography - A Feasibility Study.

Authors:  Susanne Grandl; Anikó Sztrókay-Gaul; Alberto Mittone; Sergey Gasilov; Emmanuel Brun; Alberto Bravin; Doris Mayr; Sigrid D Auweter; Karin Hellerhoff; Maximilian Reiser; Paola Coan
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.